National Minority Quality Forum Inc

COVID-19 AND INFLUENZA VACCINATION COMMUNICATIONS, EDUCATION AND TRAINING TO PROMOTE EQUITY IN BLACK AND HISPANIC COMMUNITIES - BUILDING ON SEVERAL YEARS OF GROWING EDUCATION AND TRAINING TO PROMOTE FLU VACCINE EQUITY, THE NATIONAL MINORITY QUALITY FORUM (NMQF) AND ITS CENTER FOR SUSTAINABLE HEALTH CARE QUALITY AND EQUITY (SHC) ARE PARTNERING WITH HEALTH EQUITY AND COMMUNICATIONS LEADERS TO EXPAND THEIR EFFORTS IN THE COMING YEAR, PROMOTING FLU VACCINATION AND COVID-19 VACCINATION IN BLACK AND HISPANIC COMMUNITIES. THE PURPOSE OF THE PROGRAM IS TO INCREASE FLU AND COVID-19 VACCINATION IN BLACK AND HISPANIC COMMUNITIES SUFFERING HISTORIC DISPARITIES AND HARD HIT BY COVID-19. COMMUNICATION RESOURCES FROM THE CDC AND OTHERS WILL BE REVIEWED AND ADAPTED AS NECESSARY TO BE CULTURALLY RELEVANT AND TO HAVE A SPANISH VERSION; GAPS IN THE RESOURCES WILL LEAD TO THE DEVELOPMENT OF NEW TOOLS AS WELL. THESE RESOURCES ALONG WITH EDUCATION AND TRAINING TO TRANSLATE THEIR USE INTO ACTION WILL BE STORED ON THE NMQF?S AND SHC?S WEBSITE AND DRIVE IMPLEMENTATION KIT (SHCDRIVE.ORG) AND WILL UNDERPIN A MULTIMEDIA AND MULTIFACETED INITIATIVE WITH WEEKLY WEBINARS, BIWEEKLY EMAIL COMMUNICATIONS, MONTHLY COACHING CALLS, AND PRESENTATIONS AT THE 2021 NMQF SUMMIT. THE PROGRAM OUTCOMES, INCLUDING REACH, IMPACT, AND SUSTAINABILITY WILL BE EVALUATED BY LOUISIANA STATE UNIVERSITY?S SCHOOL OF PUBLIC HEALTH. OTHER PARTNERS INCLUDE: VULT LAB, A LEADING COMMUNICATIONS FIRM DEDICATED TO PROMOTING POSITIVE OUTCOMES THROUGH DIGITAL SOCIAL MEDIA; THE UNIVERSITY OF MARYLAND?S CENTER FOR HEALTH EQUITY?S DRS. STEPHEN THOMAS AND SANDRA QUINN; THE JOHNS HOPKINS UNIVERSITY BLOOMBERG SCHOOL OF PUBLIC HEALTH?S INTERNATIONAL VACCINE ACCESS CENTER?S MS. LOIS PRIVOR-DUMM; DR. REV. TERRIS KING OF BALTIMORE?S KING ENTERPRISE GROUP; AND CO-FOUNDER AND DIRECTOR HELEN J. ARTEAGA. THE PROGRAM SEEKS TO SOLIDIFY NMQF?S AND SHC?S VACCINE EFFORTS, BECOMING CENTRAL TO PROGRAMMING THROUGHOUT THE ORGANIZATION?S PARTNERS AND PROGRAMS, RESULTING IN SUSTAINED VACCINATION EFFORTS AND EQUITY IN COMMUNITIES OF COLOR.

CONNECTING THE DOTS BETWEEN CLINICAL TRIALS & TRUSTED COMMUNITY VOICES TO PROMOTE RESEARCH PARTICIPATION AND OPTIMAL TREATMENT OF BLACK INDIVIDUALS LIVING WITH LUPUS

ADVANCING EQUITY THROUGH THE ALLIANCE FOR REPRESENTATIVE TRIALS (ARC) PROGRAM TO DIVERSIFY AND BRING INDUSTRY-SPONSORED TRIALS TO COMMUNITIES OF COLOR AND UNDERREPRESENTED COMMUNITIES - PROJECT SUMMARY / ABSTRACT BACKGROUND. REPRESENTATION OF RACIAL AND ETHNIC MINORITIES IN CLINICAL TRIALS IS NEEDED TO ENSURE THAT REGULATED MEDICAL PRODUCTS REFLECT AND TREAT THE INTENDED TREATMENT POPULATION AND PRODUCE GENERALIZABLE RESULTS; HOWEVER, LIMITED KNOWLEDGE EXISTS ON THE EFFECTIVENESS OF ACTIONABLE SOLUTIONS TO IMPROVE DIVERSITY IN CLINICAL TRIALS AS WELL AS COST-EFFICIENT WAYS TO INCREASE COMMUNITY PRACTITIONER AND CLINICIAN CAPACITY TO PARTICIPATE IN CLINICAL RESEARCH. GOAL. THE PRIMARY PROJECT GOAL IS TO DEMONSTRATE THAT MINORITY-SERVING COMMUNITY CLINICIANS CAN BE TRAINED AND CERTIFIED TO BE PRINCIPAL INVESTIGATORS (PIS) FOR RANDOMIZED CLINICAL TRIALS AND REAL WORLD STUDIES AS WELL AS UPGRADE THEIR PRACTICES AS TRIAL SITES. METHODS. TO ACHIEVE THE THE GOAL, THE ALLIANCE FOR REPRESENTATIVE CLINICAL TRIALS (ARC), A MULTI-SPONSOR PUBLIC/PRIVATE PROGRAM ORGANIZED TO DIVERSIFY AND BRING CLINICAL TRIALS TO COMMUNITIES OF COLOR AND OTHER COMMUNITIES THAT HAVE BEEN UNDERREPRESENTED IN CLINICAL TRIALS, WILL BE SCALED UP BY INCREASING THE NUMBER OF MINORITY-SERVING CLINICIANS WHO HAVE BEEN TRAINED TO BE PRINCIPAL INVESTIGATORS (PI) TO LEAD DRUG AND DEVICE RANDOMIZED CLINICAL TRIALS. WE PROPOSE TO DEVELOP THE KNOWLEDGE, PRODUCTS, AND PROCESSES NEEDED TO EXPAND THE ARC INITIATIVE. OUR RESEARCH QUESTION IS: WILL ARC BE SUCCESSFULLY ADOPTED, IMPLEMENTED, AND SUSTAINED THROUGH EXISTING CHANNELS USING THIS IMPLEMENTATION PROCESS? A CASE STUDY WILL BE IMPLEMENTED TO EVALUATE THE EFFECTIVENESS OF THE ARC INITIATIVE ON IMPROVING MINORITY-SERVING PRACTITIONERS' AND CLINICIANS' CAPACITY TO PARTICIPATE IN CLINICAL RESEARCH IN A 12-MONTH PERIOD. OBJECTIVES. THE PROPOSED PROJECT WILL TRAIN AND CERTIFY COMMUNITY CLINICIANS TO BE PIS, PLACE STUDY COORDINATORS IN THEIR PRACTICE, AND UPGRADE THEIR LOGISTICAL SYSTEMS SO THEY CAN SUPPORT CLINICAL TRIALS. ONCE CERTIFIED AS PIS, THESE PRACTICES WILL BE ENROLLED IN THE CLINICAL INVESTIGATIVE SITE NETWORK (CISN) AS A CLINICAL TRIAL SITE. CERTIFIED PRACTICES WILL IMMEDIATELY BE OFFERED THE OPPORTUNITY TO BE AN INVESTIGATIVE SITE FOR SEVERAL PRIVATELY FUNDED STUDIES THAT CISN IS MANAGING, AND CISN WILL CONTINUOUSLY REACH OUT TO PUBLIC/PRIVATE TRIAL SPONSORS TO BRING OTHER STUDY OPPORTUNITIES TO THEM. DISSEMINATION AND INNOVATION. A PROJECT EVALUATION WILL BE CONDUCTED TO ENSURE THAT THE TOOLS AND INTERVENTIONS USED ARE EFFECTIVE, RESPONSIVE, AND EQUIPPED FOR WIDESPREAD DISSEMINATION WHEN THE FUNDING ENDS. TO PREPARE FOR DISSEMINATION, WE WILL CONSULT WITH THE ASSOCIATION OF BLACK CARDIOLOGISTS TO REFINE ARC PROCESSES AND PRACTICES AND UTILIZE AN EVALUATION BOARD TO EVALUATE AND GUIDE PROJECT ACTIVITIES. PROJECT RESULTS ARE LIKELY TO IMPACT THE FIELD BY IMPROVING TECHNICAL ABILITIES AND CLINICAL PRACTICE TO: RECRUIT AND TRAIN MINORITY-SERVING COMMUNITY CLINICIANS TO IMPLEMENT CLINICAL TRIALS; CREATE A SUSTAINABLE SOLUTION TO IMPROVING THE RECRUITMENT AND RETENTION OF DIVERSE POPULATIONS IN CLINICAL TRIALS; AND CREATE AN INFRASTRUCTURE FOR COMMUNITY CLINICS TO PARTICIPATE IN CLINICAL TRIALS, INCREASING THE ACCESSIBILITY OF TRIALS TO UNDERREPRESENTED GROUPS. THE PROPOSED PROJECT IS INNOVATIVE BECAUSE IT SYSTEMATICALLY EXAMINES THE PROCESS OF EXPANDING THE ARC INITIATIVE, A POTENTIALLY SUSTAINABLE SOLUTION TO IMPROVING DIVERSITY IN CLINICAL TRIALS.